Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 425
- 试验地点
- 1
- 主要终点
- Incidence of therapeutic failure
研究概览
简要总结
In resource-limited setting, concerns remain regarding the emergence of virologic failure and high-level drug resistance mutations (DRM) during WHO recommended first-line antiretroviral therapy (ART) with non-nucleoside reverse transcriptase inhibitors (NNRTI) based regimens for Human immunodeficiency virus 1 (HIV1) infected patients. The study hypothesis is that a boosted-protease inhibitor regimen has a better outcome than a NNRTI-based regimen with a low genetic barrier to resistance.
The study is a randomized, multicenter, factorial trial (conducted in Congo), in treatment- naïve adults receiving for 96 weeks ritonavir- boosted lopinavir(LPV/r) or nevirapine (NVP) each in combination with tenofovir (TDF) /emtricitabine (FTC) or zidovudine (ZDV)/lamivudine (3TC). The primary end point is the incidence of therapeutic (clinical and/or virologic)failure by study week 24.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Antiretroviral-therapy naïve HIV-1 infected Adults
- •WHO clinical stage 3 and CD4 <350/mm3 or
- •WHO clinical stage 4 or
- •CD4 cell count < 200/mm3
- •Negative pregnancy test
排除标准
- •Hemoglobin < 8.5 g/dL (female) or 9.0 g/dL (male)
- •Estimated Glomerular Filtration Rate < 50 ml/ minute (Cockcroft-Gault equation)
- •Hepatic transaminases (AST and ALT)> 3 x upper limit of normal
- •Active tuberculosis
- •Pregnancy
- •Females who are breastfeeding
研究组 & 干预措施
nevirapine and tenofovir/emtricitabine
nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
干预措施: nevirapine (Drug)
nevirapine and tenofovir/emtricitabine
nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
干预措施: Tenofovir/emtricitabine (Drug)
lopinavir/r and tenofovir/emtricitabine
ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
干预措施: ritonavir-boosted Lopinavir (Drug)
lopinavir/r and tenofovir/emtricitabine
ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
干预措施: Tenofovir/emtricitabine (Drug)
Nevirapine and zidovudine/lamivudine
nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
干预措施: nevirapine (Drug)
Nevirapine and zidovudine/lamivudine
nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
干预措施: Zidovudine/lamivudine (Drug)
Lopinavir/r and zidovudine/lamivudine
ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
干预措施: ritonavir-boosted Lopinavir (Drug)
Lopinavir/r and zidovudine/lamivudine
ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
干预措施: Zidovudine/lamivudine (Drug)
结局指标
主要结局
Incidence of therapeutic failure
时间窗: At week 48 with follow-up until week 96
The primary end point is the proportion of patients with therapeutic failure defined as: * the occurence or relapse by week 24 of a World Health Organization (WHO) stage 4 or 3 event, or * death by week 24, or * discontinuation of study drugs due to toxicity at any time, or * virological failure defined as HIV-1 RNA \> 1000 copies/ml by week 24
次要结局
- Changes in laboratory parameters(Through week 96)
- HIV-1 RNA viral load less than 50 copies/ml(Through week 96)
- Immunologic response(Through week 96)
- HIV-1 resistance mutations(At baseline and at the time of virologic failure)
- Safety and tolerability(Through week 96)
研究者
Clumeck Nathan
Chief infectious diseases , Professor of Medicine
Centre Hospitalier Universitaire Saint Pierre